ECM
PTGX icon

ExodusPoint Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

ExodusPoint Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-124,929
Closed -$8.3M – 1960
2025
Q3 		$8.3M Buy
+124,929
New +$7.1M 0.08% 241
2025
Q1 		– Sell
-29,870
Closed -$1.15M – 1898
2024
Q4 		$1.15M Buy
+29,870
New +$1.3M 0.01% 901
2023
Q4 		– Sell
-177,125
Closed -$2.95M – 1942
2023
Q3 		$2.95M Buy
177,125
+162,471
+1,109% +$3.15M 0.03% 542
2023
Q2 		$405K Buy
+14,654
New +$367K ﹤0.01% 1427
2023
Q1 		– Sell
-90,107
Closed -$983K – 2059
2022
Q4 		$983K Sell
90,107
-18,769
-17% -$158K 0.01% 952
2022
Q3 		$918K Sell
108,876
-2,250
-2% -$21.3K 0.01% 1145
2022
Q2 		$879K Buy
+111,126
New +$1.34M 0.01% 1143
2021
Q1 		– Sell
-15,701
Closed -$317K – 2506
2020
Q4 		$317K Buy
+15,701
New +$338K ﹤0.01% 1519
2019
Q2 		– Sell
-30,119
Closed -$379K – 1286
2019
Q1 		$379K Buy
30,119
+15,919
+112% +$141K 0.03% 403
2018
Q4 		$96K Buy
+14,200
New +$113K 0.01% 312

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ExodusPoint Capital Management's PTGX Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 124,929 shares — an estimated $8.3M sold.

ExodusPoint Capital Management first reported a position in PTGX in Q4 2018 and held it in 10 quarters. The position peaked at $8.3M in Q3 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 124,929 Protagonist Therapeutics shares in Q4 2025, an estimated $8.3M.
  • ExodusPoint Capital Management first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 10 quarters.
  • ExodusPoint Capital Management's Protagonist Therapeutics position peaked at $8.3M in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.